Economic Evaluation of Positron Emission Tomography (PET) in Non Small Cell Lung Cancer (NSCLC), CHERE Working Paper 2007/6

Hayashi et al
(2005) Japan

a) CT only (If negative
surgery, If positive
chemotheraphy)

b) PET +CT ( If negative
thoractomy, if positive
chemotheraphy)

c) PET + CT (If PET
positive then
mediastinoscopy, if
negative then surgery)

Potentially
operable
NSCLC
free of Ml

Cost utility

Quality adjusted

Life Year (QALY)

Decision
Analysis

a) 4.79 LYs/

4.35 QALYs

b) 5.33 LYs/

4.93 QALYs

c) 5.68 LYs/

5.33 QALYS

n/a

c) vs a)
$4,775/QALY

c) vs b)
$7,555/QALY

Nguyen et al
(2005) Canada

a) CT (If positive then
mediastinoscopy, if
negative then surgery)

b) CT + PET (Biopsy or
mediastinoscopy to
confirm PET results)_______

Potentially
operable
NSCLC

Cost
effectiveness

LY gained

Decision
Analysis

b) vs a) 0.27
LY

b) vs a)
$1,268

b) vs a)
$4,689/LY gained

Gambhir 1996,
USA

a) CT - if positive then
Mediastinoscopy

b) CT and PET - if
positive PET or positive
CT then mediastinoscopy

c) CT and PET -
Mediastinoscopy if
discordant

Potentially
operable
NSCLC

Cost-
effectiveness

LY gained

Decision
analysis

b) vs a) +3 days

b) vs a) -
$1,154
c) vs a) -
$2267

b) Dominate a)
c) Saves
additional costs
$1,524